ERAS Forecast



Bearish<—>Bullish



80% Confidence




Bullish Case: Potential FDA approvals for ERAS-801 could trigger significant upward momentum, enhancing investor confidence and driving price recovery.




Bearish Case: High implementation costs and regulatory hurdles remain major obstacles, potentially dragging prices lower amidst market skepticism.




Potential Outcomes:
  • FDA Approval: 60% probability of increasing stock value significantly.
  • Regulatory Delays: 35% probability causing further declines.
  • Market Adoption Issues: 45% probability of impacting prices negatively.



June 18, 2025


Erasca Forecast

ERAS        Erasca
















Become a more profitable trader with AI optimized trading strategies






×

Chat with ERAS


 Ask any question about ERAS!